SDAD1 inhibitors represent a chemical class designed to specifically attenuate the function of the SDAD1 protein through various molecular mechanisms. These inhibitors work by directly interfering with the active sites or allosteric sites of SDAD1, thereby hindering its ability to interact with substrates or cofactors essential for its activity. The precise action of these inhibitors can vary; some may form covalent bonds with the protein, leading to irreversible inhibition, while others compete with natural substrates to occupy the catalytic sites, offering reversible inhibition. The design of these compounds is often based on the structure of SDAD1, with the aim to fit snugly into the protein's active site, mimicking the shape and charge of the natural substrates but without the same reactivity, effectively blocking the protein's normal function. This inhibition can downregulate the biochemical pathways that SDAD1 is involved in, ultimately suppressing the protein's role in specific signaling cascades. Since SDAD1 might play a role in a variety of cellular processes, the inhibitors can have broad implications on the cellular function by modulating this protein's activity.
The development of SDAD1 inhibitors also takes into account the dynamics of SDAD1 within a cellular environment, targeting the protein's regulation, expression, and turnover. Some inhibitors may influence the protein indirectly by interfering with its post-translational modifications, such as phosphorylation or ubiquitination, which are necessary for its full activity or degradation. Others might prevent the proper folding of the protein or promote its misfolding, leading to a non-functional state. Additionally, certain SDAD1 inhibitors can disrupt protein-protein interactions essential for the formation of functional complexes involving SDAD1, thereby preventing it from exerting its effects within those complexes. The specificity of these compounds is critical; they are engineered to affect only SDAD1, minimizing off-target effects and ensuring a high degree of selectivity in their inhibitory action. The rigorous design and mode of action of SDAD1 inhibitors underscore their role in precisely modulating the biological function of this particular protein within the intricate web of cellular signaling pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Sulindac | 38194-50-2 | sc-202823 sc-202823A sc-202823B | 1 g 5 g 10 g | $31.00 $84.00 $147.00 | 3 | |
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) that can suppress the Wnt/β-catenin signaling pathway. SDAD1 expression can be driven by Wnt signaling; therefore, inhibiting this pathway would result in the reduced activity of SDAD1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor which can downregulate protein synthesis by inhibiting the mTORC1 complex. As mTOR signaling can affect the expression of a variety of proteins, inhibiting mTORC1 may lead to a decrease in SDAD1 protein levels if SDAD1 synthesis is mTORC1 dependent. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway. Since the MAPK/ERK pathway can regulate the expression and activity of various proteins, blockade of this pathway can lead to decreased SDAD1 activity if SDAD1 is regulated by MAPK/ERK signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the PI3K/AKT signaling pathway. If SDAD1 activity is regulated by PI3K/AKT signaling, inhibition of this pathway by LY294002 could lead to a decrease in SDAD1 activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 is an inhibitor of the TGF-β receptor type I kinase that blocks TGF-β signaling. Inhibition of TGF-β signaling may result in decreased activity of downstream proteins including SDAD1 if SDAD1 is influenced by this pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor, which can lead to a decrease in actin cytoskeleton organization. If the function of SDAD1 is related to cytoskeletal dynamics, inhibition of ROCK could result in decreased functional activity of SDAD1. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
Dorsomorphin is an AMPK inhibitor which can affect cellular energy homeostasis. If SDAD1 function is linked to AMPK signaling, inhibiting AMPK could reduce SDAD1 activity. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
XAV-939 is a tankyrase inhibitor that stabilizes axin and thereby inhibits the Wnt signaling pathway. As axin stabilization leads to β-catenin degradation, this could result in reduced SDAD1 expression if it is Wnt responsive. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide is a compound known to inhibit the transcriptional activity of NF-κB. If SDAD1 expression or activity is regulated by NF-κB signaling, triptolide can potentially decrease SDAD1 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the c-Jun N-terminal kinase (JNK) which, when inhibited, can decrease the transcriptional activity of AP-1 dependent genes. If SDAD1 is regulated by JNK signaling, its activity could be decreased by this compound. |